Imunon, Inc. to Post Q3 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:IMNN)

Imunon, Inc. (NASDAQ:IMNN) – Analysts at HC Wainwright increased their Q3 2024 earnings estimates for shares of Imunon in a research note issued to investors on Thursday, August 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.40). HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Imunon’s current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Imunon’s Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($1.59) EPS, FY2025 earnings at ($0.66) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.38) EPS.

Imunon Price Performance

Imunon stock opened at $1.24 on Monday. The stock has a market cap of $11.66 million, a price-to-earnings ratio of -0.61 and a beta of 2.12. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65. The firm has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.18.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.